The new Dortmund-based biotech iDEL Therapeutics has launched with a €9 million seed round to develop a new class of cancer therapies. The financing was led by BiomedVC, with participation from NRW.Venture, Gründerfonds Ruhr and the KHAN Technology Transfer Fund II.
ADVERTISEMENT


adobe stock photos - deemerwha